Australia's TGA Adds New Class IIa Classification Rule! CDSS Exemption Provisions Updated Simultaneously - Wiselink Group-A More Controllable, Stable, and Future-Oriented Material Direction

Home > News Center > Australia's TGA Adds New Class IIa Classification Rule! CDSS Exemption Provisions Updated Simultaneously

Australia's TGA Adds New Class IIa Classification Rule! CDSS Exemption Provisions Updated Simultaneously

Time：2026-09-10 11:03:16

Australia's Therapeutic Goods Administration (TGA) has amended Part 2 of Schedule 2 to the Therapeutic Goods (Medical Devices) Regulations 2002, adding a new medical device classification rule under Clause 2.2. The amendment explicitly classifies non-invasive devices that contain only saline and are used to maintain the patency of or flush the lumen of other devices as Class IIa medical devices.

原

文

链

接

https://www.tga.gov.au/news/news-articles/updated-classification-rules-certain-combination-products

一、Products Covered by the New Rule

Typical products：Pre-filled saline flush syringes, saline locking solutions for vascular access devices.

Core defining conditions：The product is non-invasive, contains only saline, and is intended for flushing or maintaining the patency of other medical device lumens.

Key point：If a product contains added pharmaceutical ingredients, this new rule does not apply. Such products remain subject to the existing drug-device combination product regulatory rules under Clause 5.1. Do not confuse the classification logic for these two categories of products.

二、Effective Date & Transition Period

New applications (ARTG inclusion submitted after 2026-09-07)：The new classification rule applies directly; registration must be conducted as a Class IIa device.

Existing products (already registered in ARTG or applications submitted before 2026-09-07)：A 5-year transition period applies. Companies may gradually complete compliance remediation during this period.

For saline flush and locking products already marketed in Australia, immediate urgent changes are not required. However, companies are advised to initiate a product classification review early and allow sufficient time to update technical documentation.

三、CDSS Clinical Decision Support System Exemption Update

This announcement also revises the exemption provisions for Clinical Decision Support Systems (CDSS), taking effect on November 1, 2026. The revision does not expand or narrow the scope of CDSS exemptions; its core purpose is to clarify the boundaries of exemption eligibility, enabling software medical device manufacturers to quickly determine whether their products are exempt from ARTG registration.

Note：Obtaining an exemption does not mean complete deregulation. Exempt CDSS must still comply with advertising rules, adverse event reporting, and other statutory obligations.

四、Compliance Recommendations

Product classification：Carefully verify formulations and intended uses. Distinguish between pure saline flush devices and drug-containing combination devices to avoid classification errors that lead to registration rework.

Project scheduling：New project submissions should be evaluated directly as Class IIa. Existing products should develop a transition-period compliance plan, completing risk analysis and technical documentation updates in advance.

Software companies：Monitor the CDSS exemption details taking effect in November, and reassess the regulatory pathway for AI clinical decision software in Australia.

五、Conclusion

Australia's medical device regulations continue to evolve. A product classification error can, at minimum, prolong the registration cycle, and at worst, prevent the product from being marketed and sold locally. Companies expanding overseas are advised to conduct pre-regulatory product reviews in advance to mitigate compliance risks. For further inquiries, please contact Wiselink Zhihui!

Previous：MDCG 2020‑16 rev.5 Released! Decoding IVD Classification Rules under IVDR Next：Policy Update｜Russia Delays Medical Device Traceability Pilot Program

Fill Form

Whether you need more information or wish to cooperate with us, we will guide you through every step of the regulatory process. Subscribe to our newsletter for the latest global regulatory updates.